Navigation Links
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Date:8/7/2008

MEXICO CITY and SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data was presented from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV), demonstrating robust antiviral activity with a well-tolerated profile. An oral presentation of the data was given today by Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, during a late breaker session at the XVII International AIDS Conference in Mexico City.

"We are extremely pleased that the final results of the Phase 2a study presented today demonstrate that 800 mg once daily produced similar viral load reductions as 400 mg twice daily, providing final confirmation that RDEA806 works equally well given either once or twice daily. Based on the data to date, we continue to believe that RDEA806 has the potential to be a first-line therapy for the treatment of HIV," said Barry D. Quart, PharmD, Ardea's President and CEO. "We look forward to further evaluating RDEA806 and are on track to begin a Phase 2b study comparing once daily doses of RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients receiving background treatment with Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), in the third quarter of this year. A recently completed drug interaction study with RDEA806 and Truvada confirmed the lack of drug-drug interactions between these agents, paving the way for initiation of the Phase 2b study."

The Phase 2a randomized, double-blind, placebo-controlled trial evaluated the antiviral activity, pharmacokinetics, safety a
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Research and Markets ( ... "Medical Device Outsourcing - Global Strategic Business ... This report analyzes the worldwide markets for Medical ... Device Categories: Class I, Class II, and Class ... report Include - Radiology, Orthopedic, Neurology, Cardiology, and ...
(Date:4/17/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lmsnqn/medical_equipment ... Equipment Rental and Leasing - Global Strategic Business Report" ... analyzes the worldwide markets for Medical Equipment Rental and ... analytics for the US, Japan , ... Annual estimates and forecasts are provided for ...
(Date:4/17/2015)... , April 17, 2015 ASSESS ... mutation   is a viable alternative to tumour biopsy   ... in all patients with advanced NSCLC   AstraZeneca ... of plasma circulating tumour DNA (ctDNA) testing for epidermal growth ... advanced non-small cell lung cancer (NSCLC) in clinical practice. [ ...
Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Medical Equipment Rental and Leasing Market 2015-2020 - Global Strategic Business Report - Healthcare Spending Slowdown Bodes Well for Medical Equipment Leasing 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... 2011 OncologyRx Care Advantage, McKesson Specialty Health ... by Incyte Corporation as one of only ... to fill prescriptions for Jakafi (ruxolitinib), an oral prescription ... (Logo:  http://photos.prnewswire.com/prnh/20110912/DA65711LOGO ) ...
... Solos Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to ... Net Profit of $73,895.  Solos Endoscopy has consummated agreements ... for the Three Months period ending September 30, 2011. ... in a reduction of ongoing expenses by approximately $40,000 ...
Cached Medicine Technology:OncologyRx Care Advantage™ Chosen to Fill Prescriptions for Jakafi™ (ruxolitinib) 2Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2
(Date:4/19/2015)... Family and friends of Brad Baddeley are ... of Brad Baddeley event to honor his memory and ... for Brains is cheduled to take place on Sunday, April ... Lincoln, Nebraska. Participants may arrive at 12:30pm on the 26th ... cost is only $4 per game and 100% of the ...
(Date:4/18/2015)... Hills, CA (PRWEB) April 19, 2015 For ... and will proudly display for the rest of their lives, ... money obtaining them and put in a great amount of ... on a whim, they have outgrown them or simply want ... percent of people regret their tattoo, and in 2012-13 there ...
(Date:4/18/2015)... 2015 Compare-autoinsurance.org has released a new ... auto insurance policy . , Clients should no ... quotes online is safe and reliable. An insurance brokerage ... are displayed on a single web page, so drivers ... It is now possible to compare online car insurance ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancesavings.biz has ... insurance plans are cheaper during Spring. , ... auto insurance plan. Drivers should make sure they compare ... their vehicles. Clients can learn more about Spring car ... , Auto insurance quotes are becoming more and ...
(Date:4/18/2015)... PITTSBURGH, PA (PRWEB) April 18, 2015 ... store evacuation stretchers in healthcare facilities," said an inventor ... an alternative storage system." , He developed the Slyde ... bathroom doors used in healthcare facilities. It provides convenient ... that there are more stretchers available for patients. ...
Breaking Medicine News(10 mins):Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Dennis Dass, M.D. is Shattering the Past While Revealing the Future 2Health News:A Guide For Avoiding Online Auto Insurance Scams! 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2
... new and efficient strategy, using eggs alone, for creating ... the risk of rejection because the cells are compatible ... mice, the work establishes the principle of using unfertilized ... that are genetically matched to the egg donor at ...
... infected with lymphocytic choriomeningitis virus (LCMV), an infectious agent ... cause severe brain damage in a fetus. ... winter months, when rodents seek shelter in homes, said ... the University of Iowa Roy J. and Lucille A. ...
... Hospital reporting systems may significantly under-report patient safety incidents, ... on bmj.com today//. ,The authors suggest that the ... be sufficient if the NHS is to gather accurate ... safety incidents. ,Patient safety incidents are common ...
... could bankrupt the health system, warn doctors in this week’s ... population is overweight and more than one in five adults ... at high risk of multiple health problems, while the cost ... at up to 9%, and the overall social cost of ...
... past two decades are leading to more definitive diagnoses, ... for patients suffering from a condition called acromegaly. ... for Academic Affairs and director of the Burns and ... medical progress related to the condition that stems from ...
... vaccine, will hold a pride of place in the annals ... to receive certification by the European Medicines Agency, for its ... bird-flu pandemic. , ,This first generation vaccine can ... officially declares a pandemic. ,A second –generation vaccine ...
Cached Medicine News:Health News:Researchers Create Genetically-Matched Embryonic Stem Cells for Transplantation 2Health News:Researchers Create Genetically-Matched Embryonic Stem Cells for Transplantation 3Health News:Pregnant Women Can Minimize Risk Of Rodent-Based Virus 2Health News:Hospitals Miss Most Patient Safety Incidents 2Health News:Obesity Could Bankrupt the Health System, Warn Doctors 2Health News:Options Improving for Patients With Acromegaly and Gigantism 2Health News:Options Improving for Patients With Acromegaly and Gigantism 3
The Sony DSR20-MD Grade Digital Video Player/Recorder represents a giant leap in digital technology. , ,This equipment is intended to be used by physicians who teach or present medical techniques...
LCD monitors....
This monitor is designed specifically for medical applications and is UL2601-1 listed....
Standard arthroscope with telescope (4 mm) for large joints....
Medicine Products: